Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy

Figures & data

Figure 1 Y253H and T315I mutation in the ABL1 kinase domain were detected by PCR-direct sequencing before and after anti-CD19 CAR-T treatment. (A) Y253H mutation in the ABL1 kinase domain was identified in the patient after imatinib treatment for half a year. (B) T315I mutation was identified about half a year after switching from imatinib to dasatinib, while Y253H was undetectable. (C) No mutations were identified after chemotherapy followed by anti-CD19 CAR-T therapy. Colors green, red, black and blue represent nucleobases of A, T, G and C, respectively.

Figure 2 BCR-ABL1 expression level, leukocyte number and the percentage of blast cells in bone marrow before and after anti-CD19 CAR-T treatment since April 24, 2017.

Figure 3 Patient responses after infusion. (A) After infusion, the number of CAR copies in the peripheral blood continued to increase and reached the highest value on day 10. The number of CAR copies remained high even after administration 320 mg tocilizumab. No CAR copies were detected 120 days after infusion. (B) Serum cytokine levels increased after anti-CD19 CAR-T cell infusion.